A new verdict for an old convict
- 1 September 2001
- journal article
- Published by Springer Nature in Nature Genetics
- Vol. 29 (1) , 3-4
- https://doi.org/10.1038/ng0901-3
Abstract
Certain human cancers and carcinogen-induced rodent tumors commonly contain Kras2 mutations. This activated form of ras has always been described as a dominant oncogene. A new study indicates that wildtype Kras2 has properties of a tumor suppressor gene and may have the capacity to reduce the transforming potential of oncogenically activated ras.Keywords
This publication has 12 references indexed in Scilit:
- Wildtype Kras2 can inhibit lung carcinogenesis in miceNature Genetics, 2001
- Somatic activation of the K-ras oncogene causes early onset lung cancer in miceNature, 2001
- Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3Nature Genetics, 2000
- The Dominant Negative Ras Mutant, N17Ras, Can Inhibit Signaling Independently of Blocking Ras ActivationJournal of Biological Chemistry, 2000
- Increasing complexity of Ras signalingOncogene, 1998
- K-ras is an essential gene in the mouse with partial functional overlap with N-rasGenes & Development, 1997
- Predisposition to Neoplastic Transformation Caused by Gene Replacement of H- ras 1Science, 1993
- ras p21 protein promotes survival and fiber outgrowth of cultured embryonic neuronsNeuron, 1989
- A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogeneNature, 1982
- Mechanism of activation of a human oncogeneNature, 1982